---
figid: PMC7697568__cancers-12-03355-g003
figtitle: Target therapies for ligand-dependent tumors
organisms:
- NA
pmcid: PMC7697568
filename: cancers-12-03355-g003.jpg
figlink: pmc/articles/PMC7697568/figure/cancers-12-03355-f003/
number: F3
caption: Target therapies for ligand-dependent tumors. All ligand-dependent tumors
  require Wnt ligands for pathway activation and so are sensitive to porcupine inhibitors
  that impair Wnt ligand activation. RSPO3 overexpression can be antagonized by anti-RSPO3
  antibodies. Ligand-dependent GSK3 inhibition results in reduced proteasomal degradation
  to generate amino acids such as asparagine, making tumor cells sensitive to asparagine
  depletion with asparaginase treatment. Ligand-dependent tumors are characterized
  by AXIN2 repression which can be antagonized with licensed demethylating agents
  such as azacitidine.
papertitle: 'Not All Wnt Activation Is Equal: Ligand-Dependent versus Ligand-Independent
  Wnt Activation in Colorectal Cancer.'
reftext: Sam O. Kleeman, et al. Cancers (Basel). 2020 Nov;12(11):3355.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9725004
figid_alias: PMC7697568__F3
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7697568__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7697568__cancers-12-03355-g003.html
  '@type': Dataset
  description: Target therapies for ligand-dependent tumors. All ligand-dependent
    tumors require Wnt ligands for pathway activation and so are sensitive to porcupine
    inhibitors that impair Wnt ligand activation. RSPO3 overexpression can be antagonized
    by anti-RSPO3 antibodies. Ligand-dependent GSK3 inhibition results in reduced
    proteasomal degradation to generate amino acids such as asparagine, making tumor
    cells sensitive to asparagine depletion with asparaginase treatment. Ligand-dependent
    tumors are characterized by AXIN2 repression which can be antagonized with licensed
    demethylating agents such as azacitidine.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RSPO1
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - LGR4
  - LGR5
  - FZD1
  - FZD10
  - FZD2
  - FZD3
  - FZD4
  - FZD5
  - FZD6
  - FZD7
  - FZD8
  - FZD9
  - LRP6
  - LRP5
  - RNF43
  - DVL1
  - DVL1P1
  - DVL2
  - DVL3
  - AXIN1
  - AXIN2
  - CSNK1A1
  - KRT1
  - CSNK1A1L
  - APC
  - PROC
  - GSK3A
  - GSK3B
  - HNF4A
  - Amino acids
  - Asparagine
  - Azacitidine
---
